AMAG Pharma (AMAG) Reports Q1 Loss of $3.54/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
AMAG Pharmaceuticals (AMAG) PT Lowered to $13 at Cowen
May 7, 2019 3:01 PM EDTCowen analyst Ken Cacciatore lowered the price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $13.00 (from $17.00) while maintaining a Market Perform rating.
The analyst commented, "AMAG is continuing to make aggressive investments in their current new product portfolio (Intrarosa & possibly Vyleesi later... More
